Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in TNF inhibitor-inadequate response rheumatoid arthritis
NL-OMON40024Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2013
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: ACR20 response at Week 12. Started May 2013; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON40024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40024.